Clinical trial · Interventional
First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer
First-in-human Study of MATTISSE® Tissue Engineering Chamber in Adult Female After Total Mastectomy for Breast Cancer in Immediate or Delayed 2-stage Tissue Expander Reconstruction or Conversion From Implant-based to Autologous Reconstruction
NCT05460780CI-TRIAL-00087437TIDErecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a first in human, two-stage single arm non-comparative study of safety and performance. The aim of the study is to asses the safety and the clinical performance of a new device : the MATTISSE tissu engineering chamber.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Female | — | UNRESOLVED | — |
| Breast Cancer Prevent | — | UNRESOLVED | — |
| Breast Reconstruction | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MATTISSE TEC | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MATTISSE TEC
- description
- Patient included receive MATTISSE TEC
- interventionNames
- Device: MATTISSE TEC
Primary outcomes (2)
- measure
- Safety objective: To assess the 6 months surgical complications rate of MATTISSE® TEC implant-based immediate breast reconstruction. Adverse events will be recorded.
- timeFrame
- 6 months post-surgery
- description
- Minor complications include: * Superficial skin necrosis that requires only debridement * Flap necrosis * Subcutaneous hematoma: any hematoma requiring surgical exploration * Inflammatory reaction * Seroma: defined as that which requires echo-guided puncture at least once after drain removal. * Pain * Delayed wound healing/wound dehiscence: any wound healing problems, detected during clinical examination and not requiring an intervention * Implant malposition * Superficial Venous Thrombosis (Mondor disease) * Capsular contracture Major complications include: * All complications that lead to MATTISSE® TEC removal: * Skin necrosis leading to implant exposure * Infection * Implant malposition leading to implant exposure * Device failure or defect: when the implant breaks or collapses, e.g., the base separates from the shell, failure at the time of surgical placement (fracture of the TEC before placement) * Granuloma.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Criteria related to pathology: * Female patient over 18 Years old * Patient who required autologous breast reconstruction: * Immediate unilateral reconstruction after total mastectomy for early-stage breast cancer * Breast reconstruction after unilateral preventive total mastectomy * or delayed unilateral reconstruction after total mastectomy for early-stage breast cancer with a tissue expander implantation * or conversion from implant-based to autologous reconstruction: Patient who had a breast implant during a previous reconstruction after total mastectomy for cancer, and who needs to change it. * For patient with active cancer: Patient with early-stage cancer (stage 0, I or II, with tumor size \< 50mm, without lymph-node involvement) needing oncological management that does not required radiotherapy after surgery on the breast area or on the flap donor site * Patient who required Nipple sparing (NSM) or Skin sparing mastectomy (SSM) with a unique surgical approach (same for mastectomy and implant) insertion; or implant removal for patient undergoing autologous conversion, or expender removal for patient undergoing differed reconstruction. * Autologous reconstruction using Lateral Intercostal Perforator (LICAP) flap or an intercostal thoracic artery perforation flap (LTAP) if oncological conditions do not allow for LICAP harvesting. * Patient medically fit for surgery without significant comorbidities * Breast cup-size less than D * Body mass index \>20 kg/m2 or patient for whom sufficient flap volume is expected according to surgeon's assessment * Adequate hematopoietic functions Criteria related to population: * Subjects who have given free, informed and written consent to participate in the study; * Patient able to answer questionnaires, able to communicate in the language of the study country; * Subjects affiliated to a social security schema or entitled to a social security scheme. Non-inclusion Criteria: Pathology related criteria: * Patient undergoing bilateral reconstruction * Patient undergoing bilateral preventive mastectomy * Patient undergoing simultaneous contralateral breast reduction, mastopexy, and augmentation * Previous history of radiotherapy on the breast area or on the flap donor site * Previous history of breast or axillary surgery that does not allow fat flap dissection * Presence of pacemaker or metallic prosthesis making patient unsuitable for MRI * Body mass index \>30 kg/m2 * Taking medication for weight loss at the time of inclusion visit * Presence of major medical conditions that may compromise patient's health and healing * Diabetes and a history of gestational diabetes * Active smoking * Microangiopathy, Vascular history and all systemic disease (systemic Raynaud's disease) * Patient with intertrigo or infection or alteration of the surgical site confirmed pre-operatively by clinical examination * Allergy to anesthetics or contrast media * Immunocompromised patient (HIV) or patient used immunosuppressants Population related criteria * Pregnant patient * or breastfeeding patient or woman who has nursed a child three months within inclusion * Participation in a clinical trial in the 3 months prior to the initial visit * Predicted unavailability during study. * Patient deprived of liberty or under guardianship. * Patient unable to give consent Medical device related criteria * Allergy to any of the components of the medical device. EXCLUSION CRITERIA * Positive or suspicious extemporaneous sentinel node biopsy * Non integrity of LICAP and LTAP vessels, showed by the pre-operative doppler * Patient not yet implanted with MATTISSE®, whose cancer stage will finally require radiotherapy treatment
References
Publications (20)
- BACKGROUNDFindlay MW, Dolderer JH, Trost N, Craft RO, Cao Y, Cooper-White J, Stevens G, Morrison WA. Tissue-engineered breast reconstruction: bridging the gap toward large-volume tissue engineering in humans. Plast Reconstr Surg. 2011 Dec;128(6):1206-1215. doi: 10.1097/PRS.0b013e318230c5b2. PMID 22094739
- BACKGROUNDMatsuda K, Falkenberg KJ, Woods AA, Choi YS, Morrison WA, Dilley RJ. Adipose-derived stem cells promote angiogenesis and tissue formation for in vivo tissue engineering. Tissue Eng Part A. 2013 Jun;19(11-12):1327-35. doi: 10.1089/ten.TEA.2012.0391. Epub 2013 Mar 28. PMID 23394225
- RESULTHarbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F. Breast cancer. Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2. PMID 31548545
- RESULTSchmauss D, Machens HG, Harder Y. Breast Reconstruction after Mastectomy. Front Surg. 2016 Jan 19;2:71. doi: 10.3389/fsurg.2015.00071. eCollection 2015. PMID 26835456
- RESULTTzafetta K, Ahmed O, Bahia H, Jerwood D, Ramakrishnan V. Evaluation of the factors related to postmastectomy breast reconstruction. Plast Reconstr Surg. 2001 Jun;107(7):1694-701. doi: 10.1097/00006534-200106000-00009. PMID 11391187
- RESULTVega S, Smartt JM Jr, Jiang S, Selber JC, Brooks CJM, Herrera HR, Serletti JM. 500 Consecutive patients with free TRAM flap breast reconstruction: a single surgeon's experience. Plast Reconstr Surg. 2008 Aug;122(2):329-339. doi: 10.1097/PRS.0b013e31817f45cb. PMID 18626347
- RESULTDuggal CS, Grudziak J, Metcalfe DB, Carlson GW, Losken A. The effects of breast size in unilateral postmastectomy breast reconstruction. Ann Plast Surg. 2013 May;70(5):506-12. doi: 10.1097/SAP.0b013e318263f1f8. PMID 23542837